Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 11, 2012, Pages 2305-2312

  Collins, P W ^a   Moss J ^b   Knobe, K ^b,c   Groth, A ^b   Colberg, T ^b   Watson, E ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Hemophilia B; Nonacog beta pegol; Pharmacokinetic modeling; Prophylaxis; Recombinant factor IX

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9;

ARTICLE; BLEEDING; HEMOPHILIA; HUMAN; LIMIT OF QUANTITATION; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPHYLAXIS; STEADY STATE;

HEMOPHILIA B; NONACOG BETA PEGOL; PHARMACOKINETIC MODELING; PROPHYLAXIS; RECOMBINANT FACTOR IX;

CATHETERS, INDWELLING; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; HEMOPHILIA B; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; LINEAR MODELS; PHARMACOKINETICS; PHENOTYPE; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RECOMBINANT PROTEINS;

EID: 84868152441     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12000     Document Type: Article

References (33)

1. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16(Suppl. 5): 181-8.
2. Ljung R. Prophylactic therapy in haemophilia. Blood Rev 2009; 23: 267-74.
3. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 1997; 241: 395-400.
4. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
5. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). National Hemophilia Foundation website. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed 15 May 2012.
6. Guidelines for the management of hemophilia (World Federation of Hemophilia). World Federation of Hemophilia website. Available at: http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf. Accessed 15 May 2012.
7. Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, Hanley J. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498-507.
8. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
9. Uprichard J, Adamidou D, Goddard NJ, Mann HA, Yee TT. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010. Haemophilia 2012; 18: 46-9.
10. Ragni MV, Pasi KJ, White GC, Giangrande PL, Courter SG, Tubridy KL. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8: 91-7.
11. Quon DV, Logan L. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis. Haemophilia 2011; 17: e196-201.
12. Pipe SW. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program 2010; 2010: 203-9.
13. Ostergaard H, Bjelke JR, Hansen L, Petersen LC, Pedersen AA, Elm T, Moller F, Hermit MB, Holm PK, Krogh TN, Petersen JM, Ezban M, Sorensen BB, Andersen MD, Agerso H, Ahmadian H, Balling KW, Christiansen ML, Knobe K, Nichols TC, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-41.
14. Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
15. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
16. Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation models: test of significance and descriptive goodness-of-fit measures. Methods Psychol Res Online 2003; 8: 23-74.
17. Watson E, Nowack J, Hansen L, Tranholm M, Fernyhough P, Offenberg HK. Distribution of N9-GP, a glycopegylated recombinant FIX derivative, determined by quantitative whole body radiography (QWBA) and immunohistochemical (IHC) staining. J Thromb Haemost 2011; 9(Suppl. 2): 679.
18. Collins PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
19. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-97.
20. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
21. Collins PW. Personalized prophylaxis. Haemophilia 2012; 18(Suppl. 4): 131-5.
22. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; (Suppl. 77): 3-132.
23. Berntorp E. Methods of haemophilia care delivery: regular prophylaxis versus episodic treatment. Haemophilia 1995; 1: 3-7.
24. Carlsson M, Berntorp E, Bjorkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylatic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
25. Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, Schutgens RE, Biesma DH, Grobbee DE, Fischer K. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 17: 849-53.
26. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Haemophilia 1998; 4: 413-7.
27. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
28. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
29. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
30. Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597-605.
31. Bjorkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-8.
32. Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-98.
33. Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7.